Marietta Investment Partners LLC Buys 18,375 Shares of Bristol Myers Squibb Company $BMY

Marietta Investment Partners LLC increased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 50.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 54,562 shares of the biopharmaceutical company’s stock after acquiring an additional 18,375 shares during the quarter. Marietta Investment Partners LLC’s holdings in Bristol Myers Squibb were worth $2,943,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of BMY. Brighton Jones LLC increased its position in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the period. Sivia Capital Partners LLC increased its position in Bristol Myers Squibb by 59.4% during the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after acquiring an additional 2,786 shares during the period. United Bank increased its position in Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after acquiring an additional 3,277 shares during the period. Marshall Wace LLP bought a new position in Bristol Myers Squibb during the second quarter worth $221,000. Finally, Nebula Research & Development LLC bought a new position in Bristol Myers Squibb during the second quarter worth $405,000. Institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Up 0.8%

BMY opened at $54.89 on Thursday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The firm’s fifty day moving average price is $58.15 and its two-hundred day moving average price is $56.45. The company has a market capitalization of $112.09 billion, a P/E ratio of 15.42, a P/E/G ratio of 0.16 and a beta of 0.24.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter in the previous year, the company earned $1.80 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts anticipate that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Jefferies reiterated its Buy rating on Bristol Myers Squibb, which supports the stock’s valuation case and may be helping sentiment. Jefferies Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
• Positive Sentiment: Bristol Myers said Opdivo received an EU label expansion for use with AVD in newly diagnosed advanced classical Hodgkin lymphoma, a commercial win that could lift future oncology revenue. BMY Gets Opdivo Label Expansion in the EU, Update on Camzyos
• Positive Sentiment: Arcus Biosciences announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate casdatifan in kidney cancer, adding another pipeline-related catalyst. Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan…

Analyst Ratings Changes

A number of equities analysts recently issued reports on BMY shares. Morgan Stanley reaffirmed an “underweight” rating and set a $40.00 target price on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Cantor Fitzgerald lifted their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 8th. HSBC lifted their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday, March 17th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday, April 19th. Finally, UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.